Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mid-puberty withdrawal of growth hormone in adolescents with idiopathic isolated growth hormone deficiency
NL-OMON26765Recruiting
- Sponsor
- Amsterdam UMC, location VUmc
- Start
- Sep 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of somatropin in Idiopathic Isolated Growth Hormone Deficiency (IGHD) (3 arms), sponsored by Amsterdam UMC, location VUmc. Primary endpoint: Adult height minus target height SDS. Started Sep 2016; status: recruiting.
02
Drugs
somatropin
03
Conditions
Idiopathic Isolated Growth Hormone Deficiency (IGHD)
Beyond the preview
Go deeper on NL-OMON26765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26765.